1Sakka S G, Glauner A K, Bulitta J B, et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial [-J~. Antimicrob Agents Chemother, 2007,51(9) : 3304-3310. 被引量：1
7Ikawa K, Morikawa N, Sakamoto K, et al. Pharmacokinetics and pharmacodynamic assessment of imipenem in the intraperitoneal fluid of abdominal surgery patients [ J ]. Chemotherapy, 2008,54(2) : 131-139. 被引量：1
8Novelli A, Adembri C, Livi P, et al. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis[J]. Clin Pharmacokinet,2005,44(5) :539-549. 被引量：1
9Oiannoni E, Moreillon P, Cotting J, et al. Prospective determination of plasma imipenem concentrations in critically ill children[J]. Antimicrob Agents Chemother, 2006,50 (7) : 2563- 2568. 被引量：1
10Belzberg H, Zhu J, Cornwell E 3rd, etal. Imipenem levels are not predictable in the critically ill patient[J]. J Trauma, 2004, 56(1) :111-117. 被引量：1
7Bowker KE, Holt HA, Reeves DS, et al. Bactericidal activity, post antibiotic effect and modified controlled effective regrowth time of meropenem at high concentrations. J Antimicrob Chemother, 1996,38 : 1055-1060. 被引量：1
9Jones RN, Huynh HK, Biedenbach D J, et al. Doripenem (S- 4661 ), a novel carbaponem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother, 2004,54 : 144-154. 被引量：1
10Krueger WA, Bulitta J, Kinzig-Schippers M, et al. Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother, 2005,49 : 1881-1889. 被引量：1
8Afshartous D, Bauer SR, Connor M J, et al. Pharmaeokinetics and pharmacodynamics of imipenem and meropenem in critically ill patients treated with continuous venovenous hemodialysis[J]. Am J Kidney Dis, 2014, 63(1): 170-171. 被引量：1
9Blot S, Lipman J, Roberts DM, et al. The influence of acute kidney injury on antimicrobial dosing in critically ill patients: are dose reductions always necessary?[J]. Diagn Microbiol Infect Dis, 2014, 79(1): 77-84. 被引量：1
10Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient - Concepts appraised by the example of antimicrobial agents[J]. Adv Drug Deliv Rev, 2014, 77: 3-11. 被引量：1
